Inhibitor Therapeutics, Inc.
corporate_fare Company Profile
Inhibitor Therapeutics, Inc. (OTC:INTI) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 9 items for INTI at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 8/10. Across its 9 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for INTI spans 10-Q, DEF 14A, 8-K, 10-K.
Recent high-impact activity:
- Inhibitor Therapeutics Reaffirms Going Concern With Just $146,193 Cash; Insiders Extend $600K Lifeline
- Inhibitor Therapeutics Seeks Approval for 20M Share Incentive Plan Amid Going Concern
- Inhibitor Therapeutics Flags Going Concern, $3M Default Judgment, and FDA Path Forward
- Inhibitor Therapeutics Reports Going Concern, $3M Financing Fails, Litigation Initiated
- Inhibitor Therapeutics Sues Investor Over Failed $3M Financing Deal Crucial for Going Concern
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 320 shares in INTI as of the October 30, 2026 settlement, a 100.0% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 13, 2026, 100.0% of INTI volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.